Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Temsirolimus or Tipifarnib in Metastatic Melanoma
NCT00281957Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib, temsirolimus and tipifarnib in melanoma, sponsored by National Cancer Institute. Started Aug 2007; status: completed.
02
Drugs
sorafenibtemsirolimustipifarnib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00281957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00281957.